Take the Diabetes Health Pump Survey
See What's Inside
Read this FREE issue now
For healthcare professionals only
  • 12 Tips for Traveling With Diabetes
See the entire table of contents here!

You can view the current or previous issues of Diabetes Health online, in their entirety, anytime you want.
Click Here To View

See if you qualify for our free healthcare professional magazines. Click here to start your application for Pre-Diabetes Health, Diabetes Health Pharmacist and Diabetes Health Professional.

Learn More About the Professional Subscription

Free Diabetes Health e-Newsletter
Latest
Popular
Top Rated
Type 2 Issues Archives
Print | Email | Share | Comments (0)

U.S. Advisers Reject Vivus' Fat Pill

Jul 19, 2010

This press release is an announcement submitted by Reuters Health, and was not written by Diabetes Health.

The FDA will weigh the vote before making its final decision and usually follows its panelists' advice.

(Reuters) - The first new prescription weight-loss pill in more than a decade failed to win backing from U.S.health advisers, who said safety concerns about the drug outweighed its ability to help obese patients shed pounds.

Shares of Vivus Inc's sank 62 percent on Thursday after U.S. Food and Drug Administration advisers expressed concern the once-a-day pill could cause depression, memory-loss and potential birth defects if used among millions of overweight or obese Americans.

Their decision stunned investors, who had more than doubled the share price of the California biotech in the last year on hopes that safety woes would not keep the drug from market.

An FDA official was also surprised.

"When you listen to even the no votes, you got the sense that a lot of people, they weren't strongly against the drug," said Eric Colman, deputy director of FDA's division that oversees such drugs.

Shares of rival fat-pill hopefuls, Arena Pharmaceuticals Inc and Orexigen Therapeutics Inc, also sank after the vote.

Approving the drug would be "a huge public health experiment," said panelist Elaine Morrato of the University of Colorado, one of the 10 panelists who urged against FDA approval. Six others supported the drug, called Qnexa.

The FDA will weigh the vote before making its final decision and usually follows its panelists' advice.

The panel's rejection is a blow to Vivus, which has not had a U.S. product approved since 1996.

Cowen and Co analyst Ian Sanderson said it was possible for Vivus to eventually win U.S. approval, but it would first have to test it in as many as 10,000 patients, at a potential cost of $150 million.

"They'd need a partner," Sanderson said.

The California biotechnology company is seeking the FDA's green light with the hope of beating Arena and Orexigen's rival diet drugs to market.

It told FDA's outside experts that Qnexa helped many patients shed 35 to 40 pounds and that its risks were not major.

There is little doubt the drug works, panelists said, but potential side effects such as depression, memory loss, increased heart rate and birth defects were a top worry.

"This medication, in term of efficacy, is far superior than anything that's on the market. The concerns we have are with safety," said Dr. Abraham Thomas of Henry Ford Hospital in Detroit.

Panelists were also concerned since patients may take Qnexa for years, but Vivus' data only covered about 12 months.

Nearly 70 percent of people in the United States are overweight, and more than a third of them are obese, government statistics show.

"It's like instant willpower," said Erin Aycock, a clinical trial patient who lost 50 pounds on the drug but later regained most of it. "I would do anything to be back on this drug."

In a statement after the meeting, Vivus said the panel's vote was disappointing. The company had been expecting FDA's approval decision by October 28.

Vivus has said it expects data from a longer, 2-year study by the end of this quarter.

Shares of Arena closed down 8.4 percent after the vote, reversing earlier gains. Orexigen closed 10 percent lower. Vivus shares were halted during regular trading on Thursday but fell heavily as they reopened in after-hours trade.

Some analysts saw hope for Arena's candidate, lorcaserin, which tentatively faces FDA's advisers September 16 and has 2-year data. Orexigen's FDA panel is expected December 7.

(Additional reporting by Ransdell Pierson in New York and Deena Beasley in Los Angeles; Editing by John Wallace, Andre Grenon and Tim Dobbyn)

* * *

Source:

Reuters Health

http://www.reuters.com/article/idUSTRE66E0R320100716


Categories: Food, Government & Policy, Losing weight, Medications, Medications Research, Pre-Diabetes, Type 2 Issues



You May Also Be Interested In...


Comments


Add your comments about this article below. You can add comments as a registered user or anonymously. If you choose to post anonymously your comments will be sent to our moderator for approval before they appear on this page. If you choose to post as a registered user your comments will appear instantly.

When voicing your views via the comment feature, please respect the Diabetes Health community by refraining from comments that could be considered offensive to other people. Diabetes Health reserves the right to remove comments when necessary to maintain the cordial voice of the diabetes community.

For your privacy and protection, we ask that you do not include personal details such as address or telephone number in any comments posted.

Don't have your Diabetes Health Username? Register now and add your comments to all our content.

Have Your Say...


Username: Password:
Comment:
©1991-2014 Diabetes Health | Home | Privacy | Press | Advertising | Help | Contact Us | Donate | Sitemap

Diabetes Health Medical Disclaimer

The information on this site is not intended or implied to be a substitute for professional medical advice, diagnosis or treatment. All content, including text, graphics, images, and information, contained on or available through this website is for general information purposes only. Opinions expressed here are the opinions of writers, contributors, and commentators, and are not necessarily those of Diabetes Health. Never disregard professional medical advice or delay seeking medical treatment because of something you have read on or accessed through this website.